Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases.
Company profile
Ticker
NMRA
Exchange
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
RBNC Therapeutics, Inc.
SEC CIK
Corporate docs
IRS number
844367680
NMRA stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
1 Oct 24
10-Q
2024 Q2
Quarterly report
6 Aug 24
8-K
Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
6 Aug 24
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7 May 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
8-K
Other Events
15 Apr 24
S-8
Registration of securities for employees
7 Mar 24
Latest ownership filings
4
Matthew K Fust
18 Oct 24
144
Notice of proposed sale of securities
18 Oct 24
144
Notice of proposed sale of securities
17 Oct 24
4
Robert A. Lenz
11 Oct 24
144
Notice of proposed sale of securities
10 Oct 24
144
Notice of proposed sale of securities
9 Oct 24
4
Robert A. Lenz
19 Sep 24
144
Notice of proposed sale of securities
18 Sep 24
144
Notice of proposed sale of securities
17 Sep 24
4
Robert A. Lenz
16 Sep 24
Financial summary
| Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | |
|---|---|---|
| Revenue | ||
| Cost of revenue | ||
| Operating income | ||
| Operating margin | ||
| Net income | ||
| Net profit margin | ||
| Cash on hand | ||
| Change in cash | ||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 302.57 mm | 302.57 mm | 302.57 mm | 302.57 mm | 302.57 mm | |
| Cash burn (monthly) | 21.50 mm | 43.60 mm | 21.27 mm | 24.56 mm | 3.58 mm | |
| Cash used (since last report) | 90.86 mm | 184.26 mm | 89.90 mm | 103.81 mm | 15.13 mm | |
| Cash remaining | 211.71 mm | 118.31 mm | 212.67 mm | 198.76 mm | 287.44 mm | |
| Runway (months of cash) | 9.8 | 2.7 | 10.0 | 8.1 | 80.3 | |
Institutional ownership, Q2 2024
81.9% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 96 |
| Opened positions | 26 |
| Closed positions | 16 |
| Increased positions | 41 |
| Reduced positions | 13 |
| 13F shares | Current |
|---|---|
| Total value | 567.18 bn |
| Total shares | 131.13 mm |
| Total puts | 74.40 k |
| Total calls | 183.60 k |
| Total put/call ratio | 0.4 |
| Largest owners | Shares | Value |
|---|---|---|
| AMGN Amgen | 35.37 mm | $423.72 mm |
| ARCH Venture Fund XII | 31.93 mm | $401.71 mm |
| FMR | 8.62 mm | $84.76 bn |
| SFTBF SoftBank | 7.65 mm | $75.17 bn |
| T. Rowe Price Investment Management | 5.10 mm | $50.14 mm |
| BLK BlackRock | 4.60 mm | $45.25 bn |
| MIC Capital Management UK | 4.46 mm | $43.85 bn |
| ICONIQ Capital | 3.40 mm | $33.41 bn |
| Wellcome Trust | 3.31 mm | $32.53 bn |
| Vanguard | 3.27 mm | $32.18 bn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 18 Oct 24 | Fust Matthew K | Common Stock | Sell | Dispose S | No | Yes | 17.0346 | 14,049 | 239.32 k | 20,100 |
| 18 Oct 24 | Fust Matthew K | Common Stock | Option exercise | Acquire M | No | No | 2.52 | 7,844 | 19.77 k | 34,149 |
| 18 Oct 24 | Fust Matthew K | Common Stock | Option exercise | Acquire M | No | No | 8.79 | 6,205 | 54.54 k | 26,305 |
| 18 Oct 24 | Fust Matthew K | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.52 | 7,844 | 19.77 k | 85,586 |
| 18 Oct 24 | Fust Matthew K | Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.79 | 6,205 | 54.54 k | 0 |
| 17 Oct 24 | Fust Matthew K | Common Stock | Sell | Dispose S | No | Yes | 17.0103 | 7,739 | 131.64 k | 20,100 |
| 17 Oct 24 | Fust Matthew K | Common Stock | Option exercise | Acquire M | No | No | 2.52 | 2,156 | 5.43 k | 27,839 |
| 17 Oct 24 | Fust Matthew K | Common Stock | Option exercise | Acquire M | No | No | 8.79 | 1,800 | 15.82 k | 25,683 |
| 17 Oct 24 | Fust Matthew K | Common Stock | Option exercise | Acquire M | No | No | 8.32 | 3,783 | 31.47 k | 23,883 |
| 17 Oct 24 | Fust Matthew K | Stock Option Common Stock | Option exercise | Dispose M | No | No | 2.52 | 2,156 | 5.43 k | 93,430 |
News
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
5 Nov 24
JP Morgan Downgrades Neumora Therapeutics to Neutral, Lowers Price Target to $15
5 Nov 24
12 Health Care Stocks Moving In Monday's Intraday Session
21 Oct 24
Needham Reiterates Buy on Neumora Therapeutics, Maintains $23 Price Target
18 Oct 24
HC Wainwright & Co. Initiates Coverage On Neumora Therapeutics with Buy Rating, Announces Price Target of $30
1 Oct 24